Mayukh Sukhatme Sells 17,519 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Key Points

• Insider selling: Mayukh Sukhatme sold 17,519 Roivant Sciences shares for approximately $653,459, reducing his ownership by 0.09% to 18.63 million shares. He also sold more than 982,000 shares in several transactions during the surrounding week.
• Stock performance: ROIV traded at $36.30, near its 52-week high of $37.97, with a market capitalization of about $26.2 billion. The stock’s 50-day and 200-day moving averages were $34.61 and $30.43, respectively.
• Analyst and institutional sentiment: Most analysts maintain bullish ratings, producing a “Moderate Buy” consensus and an average price target of $35.14, while institutional investors own 64.76% of the company. Roivant’s latest quarter beat EPS expectations but missed revenue estimates and remained unprofitable.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) insider Mayukh Sukhatme sold 17,519 shares of the firm's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $37.30, for a total transaction of $653,458.70. Following the completion of the sale, the insider owned 18,630,739 shares in the company, valued at $694,926,564.70. The trade was a 0.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 21st, Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock. The stock was sold at an average price of $36.48, for a total transaction of $5,280,698.88.
• On Wednesday, August 19th, Mayukh Sukhatme sold 172,899 shares of Roivant Sciences stock. The stock was sold at an average price of $37.17, for a total transaction of $6,426,655.83.
• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total value of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The stock was sold at an average price of $36.73, for a total value of $5,029,879.66.

Roivant Sciences Stock Performance

NASDAQ ROIV traded down $0.54 during trading on Friday, reaching $36.30. 6,185,493 shares of the company's stock were exchanged, compared to its average volume of 5,631,176. The company has a 50 day moving average price of $34.61 and a two-hundred day moving average price of $30.43. The stock has a market cap of $26.22 billion, a P/E ratio of -68.49 and a beta of 1.12. Roivant Sciences Ltd. has a 1 year low of $11.60 and a 1 year high of $37.97.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The business had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.06 million. Research analysts forecast that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Pictet Asset Management Holding SA raised its stake in shares of Roivant Sciences by 790.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 2,312,436 shares of the company's stock worth $50,180,000 after buying an additional 2,052,693 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Roivant Sciences by 8.4% in the 4th quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company's stock valued at $912,681,000 after buying an additional 3,254,113 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of Roivant Sciences by 90.9% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 80,561 shares of the company's stock valued at $1,746,000 after buying an additional 38,354 shares in the last quarter. Nicholas Investment Partners LP boosted its stake in shares of Roivant Sciences by 13.9% in the fourth quarter. Nicholas Investment Partners LP now owns 279,856 shares of the company's stock valued at $6,073,000 after buying an additional 34,235 shares in the last quarter. Finally, Jefferies Financial Group Inc. acquired a new position in Roivant Sciences during the fourth quarter worth $76,272,000. Hedge funds and other institutional investors own 64.76% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ROIV. Sanford C. Bernstein raised shares of Roivant Sciences to a "strong-buy" rating in a report on Wednesday, July 29th. TD Cowen restated a "buy" rating on shares of Roivant Sciences in a report on Thursday, August 6th. Guggenheim increased their target price on shares of Roivant Sciences from $36.00 to $42.00 and gave the company a "buy" rating in a research report on Friday, August 7th. HC Wainwright lifted their price target on shares of Roivant Sciences from $34.00 to $41.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Roivant Sciences in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Roivant Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $35.14.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source